Monotherapy of advanced or unresectable hepatocellular carcinoma

Active Ingredient: Durvalumab

Indication for Durvalumab

Population group: only adults (18 years old or older)
Therapeutic intent: Curative procedure

Durvalumab as monotherapy is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC).

For this indication, competent medicine agencies globally authorize below treatments:

1,500 mg every 4 weeks

For:

Dosage regimens

Regimen A, in case that patient weight is > 30 kg

Intravenous, 1,500 milligrams durvalumab, once every 4 weeks.

Regimen B, in case that patient weight is ≤ 30 kg

Intravenous, 10 milligrams durvalumab per kilogram of body weight, once every 2 weeks.

Regimen C, in case that patient weight is ≤ 30 kg

Intravenous, 20 milligrams durvalumab per kilogram of body weight, once every 4 weeks.

Detailed description

Recommended dose

1,500 mg every 4 weeks.

Patients with a body weight of 30 kg or less must receive weight-based dosing, equivalent to durvalumab 10 mg/kg every 2 weeks or 20 mg/kg every 4 weeks as monotherapy until weight increases to greater than 30 kg.

Duration of therapy

Until disease progression or until unacceptable toxicity.

Dose escalation or reduction is not recommended. Treatment withholding or discontinuation may be required based on individual safety and tolerability.

Dosage considerations

It is to be administered as an intravenous infusion solution over 1 hour.

Active ingredient

Durvalumab

Durvalumab is a fully human, immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that selectively blocks the interaction of PD-L1 with PD-1 and CD80 (B7.1). Durvalumab does not induce antibody dependent cell-mediated cytotoxicity (ADCC). Selective blockade of PD-L1/PD-1 and PD-L1/CD80 interactions enhances antitumour immune responses and increases T-cell activation.

Read more about Durvalumab

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.